- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04404426
CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome (CACOLAC)
CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
Respiratory involvement of SARS-CoV2 leads to acute respiratory distress syndrome (ARDS) and significant immunosuppression (lymphopenia) exposing patients to long ventilation duration and late mortality linked to the acquisition of nosocomial infections.
Lymphopenia characteristic of severe forms of ARDS secondary to SARS-CoV2 infection may be linked to expansion of MDSCs and arginine depletion of lymphocytes.
Severe forms of COVID-19 pneumonitis are marked by persistent ARDS with acquisition of nosocomial infections as well as by prolonged lymphocytic dysfunction associated with the emergence of MDSC.
It has been found in intensive care patients hypoargininaemia, associated with the persistence of organ dysfunction (evaluated by the SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, the enteral administration of ARG was not deleterious and increased the synthesis of ornithine, suggesting a preferential use of ARG by the arginase route, without significant increase in argininaemia nor effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, is an interesting alternative to increase the availability of ARG. Recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. The hypothesis is therefore that CIT supplementation is more effective than the administration of ARG to correct hypoargininaemia, decrease lymphocyte dysfunction, correct immunosuppression and organ dysfunction in septic patients admitted to intensive care.
The main objective is to show that, in patients hospitalized in intensive care for ARDS secondary to COVID-19 pneumonia, the group of patients receiving L-citrulline for 7 days, compared to the group receiving placebo, has a score of organ failure decreased on D7 (evaluated by the SOFA score) or by the last known SOFA score if the patient has died or been resuscitated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Britanny
-
Rennes, Britanny, France, 35000
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than or equal to 18 years;
- Patients admitted for less than 48 hours in intensive care for ARDS under mechanical ventilation according to the Berlin criteria published in 2012 (JAMA);
- Origin of ARDS: COVID-19 pneumopathy confirmed by PCR (nasopharyngeal or tracheal sample);
- Life expectancy> 2 days;
- Affiliated to a social security scheme;
- Consent signed by the patient, the relative or the legal representative (except emergency procedure).
Exclusion Criteria:
- Pregnancy or breastfeeding in progress;
- State of immunosuppression defined by at least one of these criteria: continuous administration of steroids at any dose for more than a month before hospitalization, steroids in high doses (> 15 mg / kg / day of methylprednisolone or equivalent), radiotherapy or chemotherapy in the previous year, proven humoral or cellular deficiency;
- Contraindication to enteral nutrition (2016 SRLF recommendations: "Enteral nutrition probably should not be used upstream of a high-flow digestive fistula in the event of intestinal obstruction, small ischemia or digestive hemorrhage active (Strong chord) ").
- Ongoing immunosuppressive therapy such as chemotherapy, cyclophosphamide, high dose corticosteroid therapy (> 15 mg / kg / day);
- Participation in intervention research on a drug, or intervention research that may impact the immune system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L-citrulline
Administration of citrulline enterally for 7 days
|
Administration of citrulline enterally for 7 days.
|
Placebo Comparator: Placebo
Administration of placeboenterally for 7 days
|
Administration of placebo (water) enterally for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SOFA
Time Frame: Day 8
|
SOFA score for organ failures on D8 or last known SOFA score if the patient has died or been resuscitated
|
Day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and phenotype of lymphocytes
Time Frame: Days 1, 8 and 14
|
Number and phenotype of lymphocytes on days 1, 8 and 14
|
Days 1, 8 and 14
|
HLA-DR
Time Frame: Days 1, 8 and 14
|
Monocytic expression HLA-DR (Flow cytometry) on days 1, 8 and 14
|
Days 1, 8 and 14
|
Number of Myeloid-derived suppressor cells
Time Frame: Days 1, 8 and 14
|
Number of Myeloid-derived suppressor cells (Flow cytometry) on days 1, 8 and 14
|
Days 1, 8 and 14
|
Plasma cytokines / chemokines
Time Frame: Days 1, 8 and 14
|
Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-β) at days 1, 8 and 14
|
Days 1, 8 and 14
|
Repertoire T
Time Frame: Days 1, 3, 8, 10 and 14
|
Diversity of the repertoire T at days 1, 3, 8, 10 and 14
|
Days 1, 3, 8, 10 and 14
|
Lymphocyte T exhaustion
Time Frame: Days 1, 8 and 14
|
T lymphocyte exhaustion: measurement of lymphocyte apoptosis and lymphocyte proliferation on days 1, 8 and 14
|
Days 1, 8 and 14
|
Mitochondrial activity
Time Frame: Days 1, 8 and 14
|
Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of the expression of Beclin1) on days 1, 8 and 14
|
Days 1, 8 and 14
|
Plasma amino acids
Time Frame: Days 1, 8 and 14
|
Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on days 1, 8 and 14
|
Days 1, 8 and 14
|
SOFA
Time Frame: Days 3, 7, 10 and 14
|
SOFA score of organ failures on days 3, 7, 10 and 14
|
Days 3, 7, 10 and 14
|
Duration of hospitalization in intensive care
Time Frame: Day 28
|
Duration of hospitalization in intensive care (days), up to day 28 maximum
|
Day 28
|
Duration of hospital stay in hospital
Time Frame: Day 28
|
Duration of hospital stay in hospital (days), up to day 28 maximum
|
Day 28
|
Duration of mechanical ventilation
Time Frame: Day 28
|
Duration of mechanical ventilation (days), up to day 28 maximum
|
Day 28
|
Mortality in intensive care on day 28
Time Frame: Day 28
|
Mortality in intensive care on day 28
|
Day 28
|
Hospital mortality on day 28
Time Frame: Day 28
|
Hospital mortality on day 28
|
Day 28
|
Measurement of the presence of SARS-CoV2
Time Frame: Days 1, 8 and 14
|
Measurement of the presence of SARS-CoV2 in the tracheal aspiration by PCR on days 1, 8 and 14
|
Days 1, 8 and 14
|
Nosocomial infections
Time Frame: D28
|
Incidence of nosocomial infections during the intensive care unit (maximum D28).
The diagnosis of nosocomial infections will be made according to the definitions of nosocomial infections of the CDC.
An independent committee of experts will validate or not the infections
|
D28
|
Number of days of exposure to each antibiotic per 1000 days of hospitalization
Time Frame: Day 28
|
Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum day 28).
|
Day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- 35RC20_9815_CACOLAC
- CPP 1288 HPS1 (Other Identifier: CPP Ouest 6 (Brest))
- 2020-A01189-30 (Other Identifier: ID RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS Secondary to COVID-19 Pneumonia
-
University of Southern DenmarkOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaboratorsRecruitingARDS Due to COVID-19Denmark
-
Hopital of MelunCompletedCOVID-19 Pneumonia | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2France
-
Foresee Pharmaceuticals Co., Ltd.TerminatedSevere to Critical COVID 19 With Associated ARDSUnited States
-
Sciberras, Stephen M.D.Mater Dei Hospital, MaltaCompletedARDS | COVID-19 PneumoniaMalta
-
M Abdur Rahim Medical College and HospitalFirst affiliated Hospital Xi'an Jiaoting UniversityUnknownCovid19 | Covid-19 ARDSBangladesh
-
A.O. Ospedale Papa Giovanni XXIIICompletedSevere Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 InfectionItaly
-
Unity Health TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Sinai... and other collaboratorsActive, not recruitingCovid-19 | ARDSCanada
-
Universidade de Passo FundoCompletedMicrobial Colonization | Severe COVID-19 | COVID-19 Lower Respiratory Infection | Secondary Bacterial PneumoniaBrazil
-
Groupe Hospitalier Pitie-SalpetriereCMC Ambroise Paré; Centre Hospitalier Intercommunal Robert Ballanger; Centre...CompletedPneumonia | Covid-19 | ARDSFrance
-
M Abdur Rahim Medical College and HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Cox's Bazar 250 Bed District... and other collaboratorsCompletedCovid19 | Covid-19 ARDSBangladesh
Clinical Trials on L-citrulline
-
Asklepion Pharmaceuticals, LLCVanderbilt UniversityCompletedHypertension, Pulmonary | Heart Defects, CongenitalUnited States
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
University of PittsburghCompleted
-
Florida State UniversityCompletedHypertensionUnited States
-
University of Colorado, DenverCompleted
-
University of JordanUnknownType 2 Diabetes MellitusJordan
-
Florida State UniversityCompleted
-
Juliano CasonattoUnknown
-
European University CyprusCompleted